Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vytrus BiotechXMAD:VYT 69 3-Year EBITDA Growth Rate is 41.50% as of Dec. 2025, which is at its 10-year median of 41.50. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.71 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,127 Biotechnology companies, Vytrus Biotech ranks better than 79.59% on this metric.
During the past 12 months, Vytrus Biotech's average EBITDA Per Share Growth Rate was 126.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 41.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 36.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Vytrus Biotech was 121.30% per year. The lowest was 19.80% per year. And the median was 41.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Vytrus Biotech 3-Year EBITDA Growth Rate Related Terms
XMAD:VYT vs VRTX, REGN, MRNA: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Vytrus Biotech's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 41.50% mean?
Vytrus Biotech (XMAD:VYT) has a 3-Year EBITDA Growth Rate of 41.50% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vytrus Biotech and its competitors. This is near median its historical median of 41.50. Over the past decade, Vytrus Biotech's 3-Year EBITDA Growth Rate has ranged from 19.80 to 121.30. According to the industry distribution chart, Vytrus Biotech ranks #230 out of 1127 companies in the Biotechnology industry, placing it in the top 20.4%.
Is Vytrus Biotech's 3-Year EBITDA Growth Rate too high?
Vytrus Biotech's current 3-Year EBITDA Growth Rate of 41.50% is near median its 10-year median of 41.50. Over the past 10 years, this metric has ranged from a low of 19.80 to a high of 121.30. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. Vytrus Biotech's value of 41.50% is 184.2% above this industry median. Based on the distribution chart, Vytrus Biotech ranks #230 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #230 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Vytrus Biotech in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.60. Vytrus Biotech's value of 41.50% is 184.2% above this benchmark. Historically, Vytrus Biotech's own 3-Year EBITDA Growth Rate has ranged from 19.80 to 121.30 over the past decade. While the company's 10-year median is 41.50 vs. the industry median of 14.60, Vytrus Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current 3-Year EBITDA Growth Rate of 41.50% is 184.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Vytrus Biotech and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current 3-Year EBITDA Growth Rate is 41.50%, which is near median its own 10-year median of 41.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.71, compared to a current price of €16.95 — trading 196.8% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 41.50%, which is near median its 10-year median of 41.50 and 184.2% above the Biotechnology industry median of 14.60. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current 3-Year EBITDA Growth Rate is 41.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €16.95 is trading 196.8% above its estimated GF Value™ of €5.71.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
3-Year EBITDA Growth Rate: 41.50% (near median its 10-year median of 41.50)
GF Value™: €5.71 vs. price of €16.95 (196.8% above fair value)
Industry Position: 184.2% above the Biotechnology median (#230 of 1127)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score
Get the complete analysis for XMAD:VYT
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
